These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

584 related items for PubMed ID: 28644575

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
    Song Z, Zhou L, Zhang J, He L, Bai P, Xue Y.
    Dig Liver Dis; 2016 May; 48(5):506-511. PubMed ID: 26847964
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for Helicobacter pylori infection.
    Bang CS, Lim H, Jeong HM, Shin WG, Choi JH, Soh JS, Kang HS, Yang YJ, Hong JT, Shin SP, Suk KT, Lee JJ, Baik GH, Kim DJ.
    Gut Microbes; 2020 Sep 02; 11(5):1314-1323. PubMed ID: 32362221
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, Chen MJ, Chen CC, Tseng CH, Hsu YC, Lee JY, Yang TH, Luo JC, Chang CC, Chen CY, Chen PY, Shun CT, Hsu WF, Hu WH, Chen YN, Sheu BS, Lin JT, Wu JY, El-Omar EM, Wu MS, Taiwan Gastrointestinal Disease and Helicobacter Consortium.
    Lancet; 2016 Nov 12; 388(10058):2355-2365. PubMed ID: 27769562
    [Abstract] [Full Text] [Related]

  • 9. Comparison of sequential therapy and amoxicillin/tetracycline containing bismuth quadruple therapy for the first-line eradication of Helicobacter pylori: a prospective, multi-center, randomized clinical trial.
    Lee JY, Kim N, Park KS, Kim HJ, Park SM, Baik GH, Shim KN, Oh JH, Choi SC, Kim SE, Kim WH, Park SY, Kim GH, Lee BE, Jo Y, Hong SJ.
    BMC Gastroenterol; 2016 Jul 26; 16(1):79. PubMed ID: 27460100
    [Abstract] [Full Text] [Related]

  • 10. [Levofloxacin-based triple therapy versus bismuth-based quadruple therapy in the treatment of Helicobacter pylori as the rescue therapy: a meta analysis].
    Zhang M, Chen CY, Wang XT, Lyu B.
    Zhonghua Nei Ke Za Zhi; 2017 May 01; 56(5):368-374. PubMed ID: 28460509
    [Abstract] [Full Text] [Related]

  • 11. Second-line rescue treatment of Helicobacter pylori infection: Where are we now?
    Lin TF, Hsu PI.
    World J Gastroenterol; 2018 Oct 28; 24(40):4548-4553. PubMed ID: 30386104
    [Abstract] [Full Text] [Related]

  • 12. Quadruple rescue therapy for Helicobacter pylori infection after two treatment failures.
    Hsu PI, Wu DC, Chen A, Peng NJ, Tseng HH, Tsay FW, Lo GH, Lu CY, Yu FJ, Lai KH.
    Eur J Clin Invest; 2008 Jun 28; 38(6):404-9. PubMed ID: 18435764
    [Abstract] [Full Text] [Related]

  • 13. Moxifloxacin-containing triple therapy after non-bismuth quadruple therapy failure for Helicobacter pylori infection.
    Lim JH, Lee DH, Lee ST, Kim N, Park YS, Shin CM, Song IS.
    World J Gastroenterol; 2015 Dec 14; 21(46):13124-31. PubMed ID: 26673999
    [Abstract] [Full Text] [Related]

  • 14. Optimizing first line 7-day standard triple therapy for Helicobacter pylori eradication: Prolonging treatment or adding bismuth: which is better?
    Leow AH, Azmi AN, Loke MF, Vadivelu J, Graham DY, Goh KL.
    J Dig Dis; 2018 Nov 14; 19(11):674-677. PubMed ID: 30307122
    [Abstract] [Full Text] [Related]

  • 15. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial.
    Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC, Tseng HH.
    J Antimicrob Chemother; 2013 Jan 14; 68(1):222-8. PubMed ID: 22984204
    [Abstract] [Full Text] [Related]

  • 16. Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First-Line and Second-Line Regimens for Helicobacter pylori Eradication.
    Song Z, Suo B, Zhang L, Zhou L.
    Helicobacter; 2016 Dec 14; 21(6):462-470. PubMed ID: 27060292
    [Abstract] [Full Text] [Related]

  • 17. Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
    Cao Z, Chen Q, Zhang W, Liang X, Liao J, Liu W, Xiao S, Lu H.
    Scand J Gastroenterol; 2015 Dec 14; 50(10):1185-90. PubMed ID: 25881966
    [Abstract] [Full Text] [Related]

  • 18. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW, Wu DC, Yu HC, Kao SS, Lin KH, Cheng JS, Wang HM, Chen WC, Sun WC, Tsai KW, Hsu PI.
    Antimicrob Agents Chemother; 2017 Nov 14; 61(11):. PubMed ID: 28807915
    [Abstract] [Full Text] [Related]

  • 19. Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
    Gisbert JP, Perez-Aisa A, Rodrigo L, Molina-Infante J, Modolell I, Bermejo F, Castro-Fernández M, Antón R, Sacristán B, Cosme A, Barrio J, Harb Y, Gonzalez-Barcenas M, Fernandez-Bermejo M, Algaba A, Marín AC, McNicholl AG, H. pylori Study Group of the Spanish Gastroenterology Association.
    Dig Dis Sci; 2014 Feb 14; 59(2):383-9. PubMed ID: 24126798
    [Abstract] [Full Text] [Related]

  • 20. Comparison Between Sequential Therapy and Modified Bismuth-Included Quadruple Therapy for Helicobacter pylori Eradication in Chinese Patients.
    Yang X, Tan P, Song L, Lu Z.
    Am J Ther; 2016 Feb 14; 23(6):e1436-e1441. PubMed ID: 25923229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.